GW Pharmaceuticals Plc, which has an expanding portfolio of cannabinoid medicines, has raised $94 million in a follow-on offering of an earlier initial public offering on Nasdaq. The funds will be used to support development of an epilepsy compound. ---Subscribe to MedNous to access this article--- Company News
